Investor Presentaiton
Next generation of therapeutics with 67Cu
Eliminating dependency on the limited number of aging nuclear reactors for therapeutic radioisotope supply
•
•
177LU
•
Relies on antiquated,
unreliable and
government
subsidised nuclear
reactor infrastructure
Not easily scalable due
to investment requirements
for new nuclear reactor
construction
།*
Existing supply chain already strained, with demand
soon outstripping supply
Supply chain dependence on international shipments
Expensive and environmentally unfriendly inputs for
production (235U, 176Yb)
Long lived 177mLu impurity from c.a. production can
create radioactive waste handling issues at sites
67 CU
•
•
Commercially
available high
powered rhodotron
with a small
footprint (10'
diameter and 11'
tall)
Scalable with
relatively small
investments
Purpose-built supply in the markets of focus, including a US
domestic supply
Only inputs are electricity and Zinc
No long-lived impurities
Exclusive supply agreement with NorthStar Medical Isotopes
A single rhodotron can produce commercial quantities of 67Cu
CLARITY
2014 MEIE
24View entire presentation